ImClone news from FierceBiotech
NewsC&L: PDL BioPharma's L. Patrick Gage resigns
PDL BioPharma director and interim Chief Executive L. Patrick Gage resigned due to differences among the board about prioritizing company goals. Histogenics has named F. Ken Andrews president and Read more...
ALSO NOTED: ImClone hires Zuerblis for CFO post; Tekmira plans merger; Argos touts HIV data; and much more...
> ImClone Systems has hired Kenneth Zuerblis as its new chief financial officer. Zuerblis has been CFO at Enzon before his resignation in 2005 for personal reasons. Read more...
ALSO NOTED: ImClone kicks off liver cancer trial; PhRMA boosts lobbying efforts; and much more...
> Did a big boost in drug industry lobbying pay off last year? The industry's top trade group, PhRMA, spent more than $22 million lobbying in 2007--a 25 percent increase from the year before. Read more...
Is Carl Icahn out to buy Genzyme?
Rebel investor Carl Icahn (photo) has bought a stake in Genzyme, spurring speculation that he may be preparing to give it the kind of Read more...
Biotech stocks surge as investors anticipate buyouts
Over the last six weeks the U.S. Biotech Index has shot up 13 percent, a clear indication Read more...
Biogen Idec in play after Icahn makes his move
Biotech powerhouse Biogen Idec has brought in some of Wall Streets top dealmakers to explore a possible sale of the company, which would fetch well over $20 billion. In fact, says Biogen Idec, the Read more...
SPOTLIGHT: Here comes the $100B barrier
A recent conference in Philadelphia included some bold projections for biotech as the industry approaches the $100 billion mark for collective revenue. That's up from $10 billion in 1998. Keith Read more...
SPOTLIGHT: Erbitux ok'd as front-line colon cancer drug
The FDA has approved an Erbitux label update to include additional survival data. ImClone and Bristol-Myers Squibb, who make the drug, announced Read more...
More great investment timing by an ImClone CEO
Talk about great timing: new ImClone CEO John Johnson (formerly, yes, of Johnson & Johnson) did his Read more...
Erbitux clears late-stage hurdle for lung cancer
ImClone once again is feeling the tonic effects of positive trial data. Its stock price took off this morning, rising 19 percent after its European partner, Merck KGaA, reported that Erbitux helped Read more...
| Press ReleasesPRESS RELEASE: ImClone and BMS Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan ImClone Systems and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan NEW YORK, Oct. 17 -- ImClone Systems Incorporated and Read more... PRESS RELEASE: ImClone Systems Says Broader US Label for Erbitux Colorectal Cancer Drug ImClone Systems Says Broader US Label for Erbitux Colorectal Cancer Drug NEW YORK, Oct. 2 -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that the U.S. Food and Read more... PRESS RLEASE: Repligen Announces Settlement with ImClone in Erbitux Lawsuit Repligen Announces Settlement with ImClone in Erbitux Lawsuit WALTHAM, MA - September 10, 2007 - Repligen Corporation announced today it has reached a settlement with ImClone Systems, Incorporated Read more... PRESS RELEASE: ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study; Shares Soar NEW YORK -- ImClone Systems Incorporated and Bristol-Myers Squibb Company (NYSE: BMY - Read more... |
Get more ImClone coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends